InvestorsHub Logo
Followers 41
Posts 3508
Boards Moderated 2
Alias Born 09/20/2007

Re: ChuckFinley305 post# 860

Wednesday, 01/12/2022 10:56:55 AM

Wednesday, January 12, 2022 10:56:55 AM

Post# of 933
I understand your negative bias. Losing money leaves a bread taste in your mouth. Fool me once shame on you; fool me twice shame on me. Maybe I’m naive, but in this case, the facts seem overwhelming.

My bias is in favor of the story and potential that’s pretty plain to see. This is no longer Chris Nelson’s show. His interest is largely from debt conversion and amounts to 4.9%. Other management and insiders own just over 53.5% of the company.

It seems to me he’s made connections with some pretty successful people and provided himself and other investors with a remarkable opportunity.

What do we know?

1. Management has a track record of success. Check out co-founders Douglas Baum and C.Richard Piazza’s bios. Then look up Link, Sugarman, Frank, and Simon. What’s not to love?

Just check out their website. https://qsambio.com/

Then compare the management/ insider ownership here: https://www.otcmarkets.com/filing/html?id=15429489&guid=OhvwkaoGobwyOth

2. Venture capitalists have been willing to commit substantial resources to the future success of the company. I've not added up the totals but I think it's between $3 and 5$ Million.

3. We have an actual drug with a proven history of effective treatment of bone cancer.

4. We have a drug in Phase 1 FDA Trial… that is really an improved drug with fewer side effects.

5. The value of the company surpasses the current drug candidate. QSAM has an exclusive license agreement on any future drugs or treatment protocols developed by IGL Pharma, Inc, the maker or developer of Samarium-153 DOTMP, known as CycliSam.

Will all this end with success or failure? Time will tell.


Watch for opportunities with those you trust.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent QSAM News